Edgewise Therapeutics (EWTX) Change in Account Payables (2020 - 2026)
Edgewise Therapeutics (EWTX) reported Change in Account Payables of $1.4 million for Q1 2026, down 49.41% on a YoY basis from $2.9 million in Q1 2025, and up 577.23% sequentially from -$303000.0 in Q4 2025.
Edgewise Therapeutics (EWTX) Change in Account Payables (2020 - 2026) Analysis & Trends
Edgewise Therapeutics (EWTX) has 7 years of Change in Account Payables data on file, last reported at $1.4 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables fell 49.41% year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at -$1.1 million (down 129.88% YoY), and the FY2025 full-year result was $272000.0, down 84.34% from the prior year.
- Change in Account Payables grew to $1.4 million in Q1 2026, from -$303000.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $2.9 million in Q1 2025 to a low of -$2.7 million in Q2 2022.
- A 5-year average of $200588.2 and a median of $92000.0 in 2024 frame the typical range for Change in Account Payables.
- Across the five-year window, Change in Account Payables surged 1985.71% in 2022 and slumped 429.35% in 2025, its largest moves.
- Tracing EWTX's Change in Account Payables over 5 years: stood at $576000.0 in 2022, then sank by 339.93% to -$1.4 million in 2023, then surged by 106.66% to $92000.0 in 2024, then tumbled by 429.35% to -$303000.0 in 2025, then surged by 577.23% to $1.4 million in 2026.
- Business Quant data shows EWTX's Change in Account Payables at $1.4 million in Q1 2026, -$303000.0 in Q4 2025, and -$2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -42.19 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.52 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 16.86 Mn |
| 10 | Edgewise Therapeutics | 4.21 Bn | 4.21 Bn | - | 1.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.45 Mn |
| Mar 31, 2026 | 1.45 Mn |
| Dec 31, 2025 | -303,000.00 |
| Dec 31, 2025 | -303,000.00 |
| Sep 30, 2025 | -2.13 Mn |
| Sep 30, 2025 | -2.13 Mn |
| Jun 30, 2025 | -151,000.00 |
| Jun 30, 2025 | -151,000.00 |
| Mar 31, 2025 | 2.86 Mn |
| Mar 31, 2025 | 2.86 Mn |
| Dec 31, 2024 | 92,000.00 |
| Dec 31, 2024 | 92,000.00 |
| Sep 30, 2024 | -1.03 Mn |
| Sep 30, 2024 | -1.03 Mn |
| Jun 30, 2024 | 1.89 Mn |
| Jun 30, 2024 | 1.89 Mn |
| Mar 31, 2024 | 780,000.00 |
| Mar 31, 2024 | 780,000.00 |
| Dec 31, 2023 | -1.38 Mn |
| Dec 31, 2023 | -1.38 Mn |